Trial NCT04951388
Publication Liu LTC, medRxiv, 2022
Primary outcome on the report: 1) occurrence rate of solicited (local and systemic) AEs, unsolicited AEs, AESI, VAED, and SAE from Visit 2 (Day 1) to Visit 6 (28 days after second dose of study intervention); 2) neutralizing antibody titers and seroconversion rate (SCR) against live SARS-CoV-2 virus of MVC-COV1901 in adolescents as compared to young adult vaccinees at Visit 6 (Day 57).

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.